The company specifically stated that stroke was not part of the SPA. You are right that the data are not convincing. I would think it raises a red flag, and the FDA would have wanted some non inferiority in the result at least.
Do you have any explanation why stroke is not part of the SPA at all? The sample size in all arms will be 5 times bigger, so a somewhat more meaningful data should result.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.